ASCO 2020: Updates in Prostate Cancer Treatment

EP. 1: PSMA-Targeted Imaging in Prostate Cancer

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

EP. 2: Conventional Versus PSMA Imaging in Prostate Cancer

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

EP. 3: Data for Metastatic Castration-Sensitive Prostate Cancer

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

EP. 4: Clinical Trials in the Community Setting for Prostate Cancer

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

EP. 5: FDA Approved Agents for Non-Metastatic CRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

EP. 6: Overall Survival Data Presented at ASCO 2020 for nmCRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

EP. 7: Differences Between AR-Targeted Therapy in Prostate Cancer

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

EP. 8: The CARD and PROfound Trials for Metastatic CRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

EP. 9: Impact of Clinical Data on the Treatment of mCRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

EP. 10: Genetic Testing in Metastatic CRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

EP. 11: Radium-223 in Metastatic CRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

EP. 12: Emerging Therapies for Advanced Prostate Cancer

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Episodes

EP. 1: PSMA-Targeted Imaging in Prostate Cancer

EP. 2: Conventional Versus PSMA Imaging in Prostate Cancer

EP. 3: Data for Metastatic Castration-Sensitive Prostate Cancer

EP. 4: Clinical Trials in the Community Setting for Prostate Cancer

EP. 5: FDA Approved Agents for Non-Metastatic CRPC

EP. 6: Overall Survival Data Presented at ASCO 2020 for nmCRPC

EP. 7: Differences Between AR-Targeted Therapy in Prostate Cancer

EP. 8: The CARD and PROfound Trials for Metastatic CRPC

EP. 9: Impact of Clinical Data on the Treatment of mCRPC

EP. 10: Genetic Testing in Metastatic CRPC

EP. 11: Radium-223 in Metastatic CRPC

EP. 12: Emerging Therapies for Advanced Prostate Cancer

Trending on OncLive

Triplet Immunotherapy Regimen Yields Durable Responses in pMMR CRPC

FDA-Approved ADCs Prompt the Need for Revisions to the Breast Cancer Management Roadmap

Signatera Is Submitted to Japan's PMDA for Companion Diagnostic Approval in MIBC

Colorectal Cancer Isn't the Only Gastrointestinal Cancer Rising in Young Adults

Long-Term Follow-Up Confirms Tivozanib Monotherapy Efficacy in 2L/3L mRCC